The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
[0 to 20 mg] [50 ml] [30 min]
[21 to 40 mg] [100 ml] [60 min]
Stability / Miscellaneous
EXP: 1 DAY (RT).
The dilutions listed are conservative guidelines that can be used in
non-acute conditions. The infusion times were formulated to mimic the
onset of an oral formulation. (@ onset-oral= 45-60min).
Oral to IV conversion (2.5 to 1) : eg 50mg oral=20mg
IV (equivalent beta-blockade).
Lopressor may be given by IV bolus (HR, BP, and EKG should be carefully
monitored). IV therapy permits rapid control of HR and contractility.
Post MI (early tx): 5 mg IV bolus x 3 doses q2 minutes. In patients who
tolerate full 15 mg dose, oral lopressor 50mg po q6h should be started
15 min after last IV dose x 48 hours.
Unstable angina: 5 mg IV bolus x3 q2min f/b 2 to 5 mg hourly titrated
to min HR of 55 to 60 BPM or min systolic BP of 80 . May switch to oral
dosing (50 to 100mg po q6h) after IV bolus therapy.
Supraventricular tachycardias(PAT, A-fib/flutter): 5 to 15 mg (usually
5 mg) over 2.5 min at 7.5min intervals-usually a high response rate.
Early Treatment: During the early phase of definite or
suspected acute myocardial infarction, treatment with metoprolol
tartrate can be initiated as soon as possible after the patient’s
arrival in the hospital. Such treatment should be initiated in a
coronary care or similar unit immediately after the patient’s
hemodynamic condition has stabilized.
Treatment in this early phase should begin with the intravenous
administration of three bolus injections of 5 mg of metoprolol tartrate
each; the injections should be given at approximately 2-minute
intervals. During the intravenous administration of metoprolol tartrate,
blood pressure, heart rate, and electrocardiogram should be carefully
In patients who tolerate the full intravenous dose (15 mg), metoprolol
tartrate tablets, 50 mg every 6 hours, should be initiated 15 minutes
after the last intravenous dose and continued for 48 hours. Thereafter,
patients should receive a maintenance dosage of 100 mg twice daily (see
Late Treatment below).
Patients who appear not to tolerate the full intravenous dose should be
started on metoprolol tartrate tablets either 25 mg or 50 mg every 6
hours (depending on the degree of intolerance) 15 minutes after the
last intravenous dose or as soon as their clinical condition allows. In
patients with severe intolerance, treatment with metoprolol should be
Late Treatment: Patients with contraindications to
treatment during the early phase of suspected or definite myocardial
infarction, patients who appear not to tolerate the full early
treatment, and patients in whom the physician wishes to delay therapy
for any other reason should be started on metoprolol tartrate tablets,
100 mg twice daily, as soon as their clinical condition allows. Therapy
should be continued for at least 3 months. Although the efficacy of
metoprolol beyond 3 months has not been conclusively established, data
from studies with other beta blockers suggest that treatment should be
continued for 1 to 3 years.
Note: Parenteral drug products should be inspected visually for
particulate matter and discoloration prior to administration, whenever
solution and container permit.
Metoprolol Tartrate Injection, USP is available as:
cartridges per carton
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room
Temperature.] Do not freeze.
PROTECT FROM LIGHT. Retain in carton until time of use.
Discard unused portion.
Revised: February, 2008
Hospira, Inc., Lake Forest, IL 60045 USA
Source: [package insert]
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.